Peptides News and Research

RSS

Blavatnik Biomedical Accelerator funds advanced biomedical research projects

A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.

20 Aug 2015

H1N1 vaccine developed at UNMC to be evaluated in animal study

An H1N1 vaccine developed at the University of Nebraska Medical Center will enter a definitive round of testing this month, and researchers hope to establish its ability to ward off the virus.

20 Aug 2015

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential. Palatin's lead product under development is bremelanotide for the treatment of female sexual dysfunction (FSD).

19 Aug 2015

Rhythm Metabolic completes $40 million Series A financing

Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway.

13 Aug 2015

Dipexium reports net loss of $4.0 million for second quarter 2015

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended June 30, 2015.

13 Aug 2015

New MRI contrast agent detects tiny breast cancer tumors, micrometastases

Researchers at Case Western Reserve University have developed a magnetic resonance imaging (MRI) contrast agent that detects much smaller aggressive breast cancer tumors and micrometastases than current agents can identify.

13 Aug 2015

New approach may offer improved way to detect early breast cancer

Researchers have shown that magnetic resonance imaging (MRI) can detect the earliest signs of breast cancer recurrence and fast-growing tumors. Their approach detects micromestastases, breakaway tumor cells with the potential to develop into dangerous secondary breast cancer tumors elsewhere in the body.

12 Aug 2015

Scientists decipher new molecular signaling path that prompts protein degradation in muscle

Patients in advanced states of myocardial insufficiency generally lose their muscle mass and muscle strength. Indeed a fact that until now has negatively impacted the clinical course of the disease and that has resulted in poor prognoses for patients. Such pathological muscle loss impacts the skeletal muscles in particular.

11 Aug 2015

LA BioMed's Nagendra Mishra to be honored with 2015 ICAAC Young Investigator Award

Nagendra Mishra, PhD, a Los Angeles Biomedical Research Institute researcher will be honored by the American Society of Microbiology with a 2015 Interscience Conference of Antimicrobial Agents and Chemotherapy Young Investigator Award during the conference Sept. 17-21 in San Diego.

11 Aug 2015

Low GLSRV heralds adverse outcomes in PAH patients

Impaired global longitudinal strain of the right ventricle predicts adverse outcomes in patients with pulmonary arterial hypertension, say investigators.

10 Aug 2015

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced an Exclusive Channel Collaboration (ECC) to pursue the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder.

10 Aug 2015

Study may lead to effective antimicrobial treatment strategies for people with uncontrolled diabetes

Case Western Reserve scientists may have uncovered a molecular mechanism that sets into motion dangerous infection in the feet and hands often occurring with uncontrolled diabetes. It appears that high blood sugar unleashes destructive molecules that interfere with the body's natural infection-control defenses.

7 Aug 2015

Researchers show how microbiota protects against type 1 diabetes development

Our bodies have ten times the amount of microbes than human cells. This set of bacteria is called microbiota. In some instances, bacteria known as pathogens can cause infectious diseases. However, these micro-organisms can also protect us from certain diseases. Researchers from Inserm, Paris Descartes University and the CNRS (French National Centre for Scientific Research), through collaboration with teams from China and Sweden, have recently shown how microbiota protects against the development of type 1 diabetes.

7 Aug 2015

Scientists successfully test new tumor diagnosis method

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf, in cooperation with colleagues at the University of Zurich and the Ruhr-Universität Bochum, have for the first time successfully tested a new tumor diagnosis method under near-real conditions. The new method first sends out an antibody as a "spy" to detect the diseased cells and then binds to them.

4 Aug 2015

Atomic level images reveal how neuropeptide hormone neurotensin may activate its receptors

Many hormones and neurotransmitters work by binding to receptors on a cell's exterior surface. This activates receptors causing them to twist, turn and spark chemical reactions inside cells.

3 Aug 2015

Natural protein fragment produced in the brain can inhibit enzyme implicated in Alzheimer's disease

For the first time, UCLA researchers have shown that a natural protein fragment produced in the brain can act as an inhibitor of a key enzyme implicated in the onset of Alzheimer's disease, a finding that could lead to the development of new drugs to treat the disease.

30 Jul 2015

Moerae announces initiation of second MMI-0100 Phase 1 clinical trial for pulmonary disorders

Moerae Matrix Inc. announced today the initiation of its second Phase 1 clinical trial with MMI-0100, a first-in-class inhibitor of MAPKAP kinase 2 (MK2) that is being developed for pulmonary disorders characterized by inflammation and fibrosis. The study, conducted in the United Kingdom, is a double-blind, two-way cross-over design lipopolysaccharide (LPS) challenge study further evaluating the safety and tolerability of MMI-0100 when given via inhalation to healthy subjects who smoke.

29 Jul 2015

New study estimates link between coffee consumption habits and incidence of mild cognitive impairment

A new study by researchers at the University of Bari Aldo Moro, Bari, Italy, Geriatric Unit & Laboratory of Gerontology and Geriatrics, IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Foggia, Italy, and Istituto Superiore di Sanità, Roma, Italy, estimates the association between change or constant habits in coffee consumption and the incidence of mild cognitive impairment (MCI), evaluating 1,445 individuals recruited from 5,632 subjects, aged 65-84 year old, from the Italian Longitudinal Study on Aging (ILSA), a population-based sample from eight Italian municipalities with a 3.5-year median follow-up.

29 Jul 2015

Brazilian cardiovascular researcher receives Georg Forster Research Award

The cardiovascular researcher Professor Robson Augusto Souza dos Santos of the Federal University of Minas Gerais in Belo Horizonte, Brazil, has been awarded the Georg Forster Research Award of the Alexander von Humboldt Foundation.

28 Jul 2015

GLP-2 therapy may help fight neonatal parenteral nutrition-associated liver disease

A new study finds that exogenous glucagon-like peptide 2 (GLP-2) treatment may help fight neonatal parenteral nutrition-associated liver disease (PNALD).

28 Jul 2015

Peptides News and Research

Blavatnik Biomedical Accelerator funds advanced biomedical research projects

H1N1 vaccine developed at UNMC to be evaluated in animal study

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Rhythm Metabolic completes $40 million Series A financing

Dipexium reports net loss of $4.0 million for second quarter 2015

New MRI contrast agent detects tiny breast cancer tumors, micrometastases

New approach may offer improved way to detect early breast cancer

Scientists decipher new molecular signaling path that prompts protein degradation in muscle

LA BioMed's Nagendra Mishra to be honored with 2015 ICAAC Young Investigator Award

Low GLSRV heralds adverse outcomes in PAH patients

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Study may lead to effective antimicrobial treatment strategies for people with uncontrolled diabetes

Researchers show how microbiota protects against type 1 diabetes development

Scientists successfully test new tumor diagnosis method

Atomic level images reveal how neuropeptide hormone neurotensin may activate its receptors

Natural protein fragment produced in the brain can inhibit enzyme implicated in Alzheimer's disease

Moerae announces initiation of second MMI-0100 Phase 1 clinical trial for pulmonary disorders

New study estimates link between coffee consumption habits and incidence of mild cognitive impairment

Brazilian cardiovascular researcher receives Georg Forster Research Award

GLP-2 therapy may help fight neonatal parenteral nutrition-associated liver disease

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News